Steward Partners Investment Advisory’s BioCryst Pharmaceuticals BCRX Stock Holding History

Steward Partners Investment Advisory’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-600	Closed	-$4.55K	–	4325
2025 Q3	$4.55K	Hold	600	–	–	﹤0.01%	3686
2025 Q2	$5.38K	Hold	600	–	–	﹤0.01%	3454
2025 Q1	$4.5K	Buy	+600	New	+$4.84K	﹤0.01%	3407
2022 Q1	–	Sell	-150	Closed	-$2K	–	3283
2021 Q4	$2K	Buy	+150	New	+$1.99K	﹤0.01%	3002
2021 Q2	–	Sell	-1,000	Closed	-$10.2K	–	7108
2021 Q1	$10.2K	Buy	+1,000	New	+$10.3K	﹤0.01%	2777

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steward Partners Investment Advisory's BCRX Position: Q4 2025 in Review

Steward Partners Investment Advisory sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 600 shares — an estimated $4.55K sold.

Steward Partners Investment Advisory first reported a position in BCRX in Q1 2021 and held it in 5 quarters. The position peaked at $10.2K in Q1 2021. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Steward Partners Investment Advisory reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Steward Partners Investment Advisory sold 600 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $4.55K.
Steward Partners Investment Advisory first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Steward Partners Investment Advisory's BioCryst Pharmaceuticals position peaked at $10.2K in Q1 2021.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2025, filed 12 Feb 2026.